GLP-1 medicines: benefits beyond weight loss

Evidence and US product-labeling date: September 22, 2026.

Which medicine, which people, which benefit?

The strongest answer comes from matching a claim to the actual trial. Injectable semaglutide reduced cardiovascular events in people who already had cardiovascular disease. Oral semaglutide did not slow early symptomatic Alzheimer's disease. Both findings can be true because the studies asked different questions. [1] [8]

GLP-1, short for glucagon-like peptide-1, is a hormone. Semaglutide acts on its receptor. This article focuses on semaglutide because that is what the trials below tested. Their findings should not automatically be transferred to other GLP-1 medicines or drugs that also act on other hormone receptors.

• Shown: specific trials found fewer cardiovascular events, better kidney outcomes, improved heart-failure symptoms, less knee pain or favorable liver-biopsy changes. These are different kinds of benefit in different patient groups. [1] [3] [5] [6] [7] [13]

• Limits: the benefits concern the populations and conditions studied. The Alzheimer's trials did not show slower clinical decline, and a biological-age estimate is not a substitute for such an outcome. [8] [14]

• What would change the assessment: trials measuring the claimed benefit in the relevant population—for example, confirmed clinical liver outcomes or replicated improvements in function—alongside the treatment's harms.

SELECT: fewer cardiovascular events

SELECT randomly assigned 17,604 adults aged at least 45 to injectable semaglutide or placebo. They had overweight or obesity (a body mass index of at least 27), established cardiovascular disease and no history of diabetes. Average follow-up was 39.8 months. [1]

The primary outcome combined cardiovascular death, nonfatal heart attack and nonfatal stroke. An event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. The hazard ratio was 0.80, with a 95% confidence interval of 0.72–0.90. This represents a 20% lower relative hazard of the combined outcome during follow-up. The difference between the observed proportions was 1.5 percentage points. [1]

A hazard ratio compares event rates over time; 1 means no difference. The relative and absolute comparisons answer different questions. “Twenty percent lower” does not mean that 20 of every 100 treated people avoided an event, or that people lived 20% longer. Starting risk matters: SELECT participants already had cardiovascular disease. A confidence interval expresses uncertainty around an estimate; this one supported a reduction in the studied outcome.

On March 8, 2024, the US Food and Drug Administration, or FDA, approved a cardiovascular-risk-reduction indication for Wegovy injection in adults with established cardiovascular disease and overweight or obesity. That is a specific prevention benefit, not a general anti-aging indication. [2]

FLOW: kidney outcomes and mortality in a high-risk group

FLOW randomly assigned 3,533 people who had both type 2 diabetes and chronic kidney disease to injectable semaglutide or placebo. Its primary outcome combined kidney failure, a major sustained decline in the kidneys' filtering capacity, or death from kidney-related or cardiovascular causes. It tested clinical outcomes, not only blood glucose. [3]

After a median 3.4 years, the primary outcome had occurred less often with semaglutide: 331 versus 410 first events, with a hazard ratio of 0.76. Early stopping was recommended at a planned interim analysis. Death from any cause was also less frequent, with a hazard ratio of 0.80. This was a secondary outcome chosen in advance and included in the trial's confirmatory statistical testing. [3]

This lower death rate is an important finding for the high-risk population studied. Its size cannot be assumed for otherwise healthy adults at lower risk. The combined primary result also should not be presented as a result for kidney failure alone.

The US Ozempic injection label includes reducing the risk of sustained kidney-filtration decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. [4]

Symptoms and tissue changes can also matter

Not every useful outcome is a mortality result. Less breathlessness, greater walking capacity or less knee pain can make daily life easier. The exact outcome still needs to remain visible.

In STEP-HFpEF, preserved ejection fraction means that the heart still ejects a relatively normal proportion of the blood in its pumping chamber with each beat, despite heart failure. People can still have substantial symptoms. Semaglutide improved the heart-failure health-status score and increased six-minute walking distance more than placebo; the between-group difference in walking improvement was 20.3 meters, with a 95% confidence interval of 8.6–32.1 meters. [5]

MASH is an inflammatory form of metabolic fatty liver disease. Fibrosis means scarring; F2–F3 denotes moderate-to-advanced scarring before cirrhosis, the most advanced stage. In ESSENCE’s 72-week interim analysis, MASH resolved without worsening fibrosis in 62.9% with semaglutide versus 34.3% with placebo. Fibrosis improved without worsening steatohepatitis—the liver inflammation—in 36.8% versus 22.4%. [13]

Those tissue findings supported the FDA’s August 15, 2025 accelerated approval of Wegovy injection for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. This pathway uses an earlier indicator of benefit; continued approval may depend on confirmation of clinical benefit. A biopsy can detect changes before enough liver-failure, transplant or death events occur for a reliable comparison. The biopsy and clinical-outcome evidence complement each other, but they are not interchangeable. [6] [10]

Similarly, STEP 9’s pain and function improvements are useful without implying that semaglutide rebuilt a knee joint. A trial can establish the overall effect of treatment without determining how much came from weight loss, reduced load on the joint or another biological pathway. [7]

The Alzheimer's trials did not confirm slower decline

EVOKE and EVOKE+ tested oral semaglutide against placebo in people with amyloid-confirmed early symptomatic Alzheimer's disease. Amyloid confirmation provided biological evidence supporting the diagnosis. Together, the trials randomized 3,808 adults aged 55–85. [8]

The primary endpoint was change over 104 weeks on the Clinical Dementia Rating–Sum of Boxes, a measure of cognitive and functional impairment. Neither trial showed a statistically significant slowing of clinical progression compared with placebo. [8]

Novo Nordisk announced the negative topline results on November 24, 2025. The original trial paper appeared online in The Lancet on March 19, 2026. These are separate milestones: the initial result came in 2025, followed by the journal publication in 2026. [8] [9]

The sponsor's initial announcement reported improvements in Alzheimer's-related biomarkers. Those changes did not translate into slower clinical decline. It is a direct example of why a biological signal cannot replace evidence about how people think, function or feel. [9]

The result concerns early symptomatic Alzheimer's disease and the tested oral regimen. It does not settle every possible GLP-1 approach to every form of dementia. It does mean semaglutide should not be described as a demonstrated treatment for slowing early Alzheimer's progression. [8]

Aging-clock findings answer another question

A 2026 analysis examined paired blood samples from 84 participants in a 32-week randomized trial of semaglutide versus placebo for HIV-associated lipohypertrophy, or abnormal central fat accumulation. Several DNA-methylation clocks favored semaglutide; other clocks did not differ significantly. These clocks estimate biological aging from chemical marks on DNA. [14]

The analysis was exploratory and developed after the parent trial was designed. That trial's main outcome was visceral fat, the fat around internal organs. The clock analysis did not adjust for the number of comparisons, which increases the chance of apparently positive findings. Eighty-four was the paired-sample group, not the number originally randomized. [14]

The findings are a reason for further research. They do not by themselves show improved function in particular organs. A short study of blood-based models in a selected HIV population cannot answer those questions. It also does not overturn the Alzheimer's results, which measured clinical decline in a different group. [8] [14]

Less lean mass does not automatically mean less strength

An exploratory STEP 1 substudy using an X-ray-based body-composition scan called DXA followed 140 participants for 68 weeks. Reported as a conference abstract, it found reductions in both fat mass and lean body mass with semaglutide. Lean mass fell by 9.7% from the semaglutide group's starting value, while fat mass fell more. This 9.7% is a change within that group, not an effect calculated by subtracting the placebo result. [11]

The proportion of the body classified as lean increased even though its absolute amount decreased. That can happen when the total body mass falls faster: a larger share of a smaller total need not be a larger amount. Absolute quantities and percentages are both needed.

DXA lean mass is not a direct test of muscle strength. The substudy did not demonstrate a matching percentage loss of strength. Losing lean mass deserves attention, especially when a person already has limited strength or nutritional reserve, but a scan alone does not establish how well they can climb stairs, rise from a chair or carry groceries.

A clinical discussion therefore needs to include eating adequately, changes in strength and mobility, and whether the overall treatment benefit remains favorable. STEP-HFpEF's improved walking performance also shows why a body-composition finding from one population cannot automatically be turned into a claim of worse function in another. [5] [11]

Can an additional medicine preserve muscle during weight loss?

The 2026 BELIEVE phase 2 trial randomized 507 adults with obesity, or overweight plus a related complication, to bimagrumab, semaglutide, combinations or placebo. Of these, 377 completed the 48-week primary treatment period. [12]

Adding bimagrumab, an investigational antibody, reduced fat and limited lean-mass loss. It did not eliminate that loss: average lean mass still declined in the combination groups. One combination showed a statistically significant grip-strength advantage over placebo in exploratory testing, but most treatment groups did not. [12]

The main endpoint was body weight, not prevention of disability. Participants knew whether they received semaglutide, although the antibody assignment was blinded. Together with the incomplete follow-up and exploratory comparisons, these features limit the conclusions. This is useful combination-treatment research, not evidence that a routine muscle-preserving add-on has been established. [12]

Product labels and side effects remain part of the decision

The US Wegovy prescribing information distinguishes injection from tablets. Both have adult cardiovascular-risk and weight-management indications in specified populations; the MASH indication described here is for the injection. Ozempic injection has its own diabetes, cardiovascular and kidney indications. The shared active ingredient does not erase differences in formulation, indication or supporting evidence. [4] [10]

Tolerability affects whether a treatment remains worthwhile. In SELECT, adverse events led to permanent discontinuation in 16.6% of the semaglutide group versus 8.2% of the placebo group. [1]

The US labels describe stomach and intestinal side effects and cautions including inflammation of the pancreas (pancreatitis), gallbladder problems and dehydration-related kidney injury. They also list circumstances in which the products should not be used. The thyroid-tumor warning is based on rodent findings; whether the same effect occurs in humans is unknown. [4] [10]

How Healthy Longevity Clinic experts evaluate the evidence

For a reader asking whether GLP-1 treatment offers more than weight loss, the answer can be clearly positive when the medicine, condition and outcome match. SELECT demonstrated fewer cardiovascular events in people with established cardiovascular disease and overweight or obesity, without diabetes. FLOW demonstrated kidney-related benefit and lower mortality in people with both type 2 diabetes and chronic kidney disease. These are substantial clinical findings, not merely better-looking laboratory values. [1] [3]

The distinction that prevents overreach is between a demonstrated benefit for a defined condition and a general claim to slow aging. In SELECT, the 20% lower relative hazard came with a 1.5-percentage-point difference in the proportions with an event. Likewise, a liver-biopsy change, a blood-based aging clock and preserved ability to climb stairs are different outcomes. The negative Alzheimer's trials make this distinction concrete: favorable biomarkers did not yield slower clinical decline. [1] [6] [8] [9] [14]

For the clinical conversation, identify the health problem and the outcome that would justify treatment, then consider starting risk, the exact product, side effects, nutrition and functional ability. When muscle is the concern, weight and lean mass should be considered alongside actual strength and mobility. More persuasive evidence for broader healthy-aging claims would show durable clinical benefits in the proposed population, confirm liver outcomes beyond biopsies and replicate function gains without unacceptable harms. A new marker or promising combination alone does not fill that gap.

Three questions for a clinical discussion

1. Which health problem are we treating, and did a trial of this exact medicine and formulation show the outcome we want in people like me?

2. What is the likely absolute benefit at my starting risk, and how does it compare with side effects and the chance of stopping treatment?

3. How will nutrition, strength, walking ability and symptoms be assessed alongside weight and body composition?

Common questions

Do these medicines only work by making people lighter?

The trials establish overall treatment effects on specific outcomes, including cardiovascular events and kidney outcomes. They do not necessarily separate how much benefit came from weight loss from how much came through another biological pathway. A proven benefit does not require every mechanism to have been resolved. [1] [3] [7]

Does the Alzheimer's result cancel the heart and kidney benefits?

No. The studies used different formulations in different populations and measured different outcomes. The negative oral-semaglutide Alzheimer's result does not erase the positive injectable-semaglutide cardiovascular and kidney trials. [1] [3] [8]

Does a 9.7% fall in lean mass mean a 9.7% loss of strength?

No. That number was a within-group change in a 140-person exploratory body-composition substudy reported as a conference abstract. It was not a placebo-adjusted strength result. Strength and daily function need their own measurements. [11]

Is the liver indication also for Wegovy tablets?

The US MASH indication described here is for Wegovy injection. Tablet and injection indications should be read separately even though both contain semaglutide. [10]